Article
Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies.
Oncotarget - 1 Jun 2011
Passamonti Francesco, Maffioli Margherita, Caramazza Domenica, Cazzola Mario
Abstract excerpt
Most BCR-ABL1-negative myeloproliferative neoplasms (MPN) carry an activating JAK2 mutation. Approximately 96% of patients with polycythemia vera (PV) harbors the V617F mutation in JAK2 exon 14, whereas the minority of JAK2 (V617F)-negative subjects shows several mutations in exon 12. Other mutation events as MPL, TET2, LNK, EZH2 have been described in chronic phase, while NF1, IDH1, IDH2, ASX1, CBL and Ikaros in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.